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Background: Community Pharmacists, being ﬁrst point of con-
tact for peoplewith symptoms are in the suitable position to detect
the chest symptomatic cases. Since couple of years, pharmacists are
being trained by Indian Pharmaceutical Association (IPA) jointly
with Revised National Tuberculosis Control Programme (RNTCP)
and with support of Lilly MDR TB Partnership. IPA has been work-
ing in state of Maharashtra in various districts as well as spreading
this work to other states namely Madhya Pradesh, Goa, Tamilnadu
and Gujarat.
Methods&Materials: Trainingmanual jointly developedby IPA
and Central TB Division,Ministry of Health and FamilyWelfarewas
used for training community pharmacists. Training sessions pro-
vided information on TB, DOTS protocols, role of pharmacists (how
to identify a case,whom to refer,where to refer the case, how to use
“Laboratory Form for SputumExamination” (Referral Form), how to
guide the case about medication) and the signiﬁcance of commu-
nication skills. Copy of list of the Designated Microscopy Centers
(DMCs) and list of contact details of RNTCP staff was given to each
participant pharmacist. Interactive sessions for RNTCP ﬁeld staff
and pharmacists were organized to develop effective partnership.
Results: As per the data from April 2014 to April 2015, IPA has
trained 438 pharmacists. Post training, pharmacists were followed
up by IPA and were encouraged to refer chest symptomatic cases.
Out of 180 referred cases, 24 were found to be TB cases. The train-
ing was proven as quite effective in ﬁnding out the cases from the
community. Most of the trained pharmacists started referring the
cases to nearby DMCs yet quite few cases didn’t reach the DMCs
due to various reasons. The pharmacists’ work was continuously
acknowledged by media boosting their spirits up.
Conclusion: Pharmacists, if trained and followed up effectively,
can reach the unreached and ﬁnd out the chest symptomatic cases
coming to the pharmacy from the community. Pharmacists have
huge potential for contributing to the WHO stop TB theme; “Find,
Treat, Cure Everyone”. RNTCP should engage all care providers
including pharmacists for TB prevention and control.
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Background: Little is known on prevalence, risk factors and
clinical outcomes of rifampicin-resistant tuberculosis (RR-TB) in
Bukavu.
Methods & Materials: We conducted a secondary analysis on
a database containing clinical and RR-TB data collected cross-
sectionally using the Xpert MTB/RIF assay at Provincial General
Referral Hospital (PGRH) of Bukavu. The primary outcome was RR-
TB prevalence. A multivariate logistic regression was performed to
identify independent risk factors of RR-TB.
Results: Of 225 participants analyzed, 65.8% were male. The
mean (SD) age was 34.9 (16.8) years. 27 of 85 patients (12.0%) with
HIV were on antiretroviral therapy. 167 (74.2%) patients had pul-
monary tuberculosis (TB); 131 (58.2%) of these were TB sputum
smear-positive. 85 (37.8%)wereHIV positive. Of note, 45 (20%) par-
ticipants were TB retreatment cases. The prevalence of RR-TB was
8.9% (95% CI 5.5 – 13.4). Overall, 28 (12.4%) deaths were recorded
of which 6 deaths (30%) occurred in RR-TB group (P=0.013), 3
(75%) deaths among 4 HIV positive and RR-TB co-infected patients
(P =0.03). Risk factors independently associated with RR-TB were:
retreatment cases vs. new TB cases (adjusted odds ratio [aOR] =5.5,
95% CI 0.9 – 32), P =0.06); and having a previous TB treatment
failure ([aOR] =17.6, 95% CI 2.2 – 142, P =0.007).
Conclusion: We are documenting a relatively high prevalence
of RR-TB in patients at PGRH of Bukavu and the major risk fac-
tor being previous TB therapy failure. Both primary and acquired
TB drug resistance are common in this setting, therefore, there is
a need for strengthening the quality of the TB control program
in this setting. This can be achieved through increased availabil-
ity and expansion of diagnostic services, including Xpert MTB/RIF
and other drug susceptibility testing facilities to be used when TB
is suspected and/or diagnosed. This will assist in optimizing the
suitability of RR-TB treatment regimen. Finally, there is an urgent
need for the development of effective drugs for the management
of RR-TB.
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